Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 139

1.

MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators.

Nilsson EM, Laursen KB, Whitchurch J, McWilliam A, Ødum N, Persson JL, Heery DM, Gudas LJ, Mongan NP.

Oncotarget. 2015 Nov 3;6(34):35710-25. doi: 10.18632/oncotarget.5958.

2.

A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants.

Sun F, Indran IR, Zhang ZW, Tan MH, Li Y, Lim ZL, Hua R, Yang C, Soon FF, Li J, Xu HE, Cheung E, Yong EL.

Carcinogenesis. 2015 Jul;36(7):757-68. doi: 10.1093/carcin/bgv040. Epub 2015 Apr 23.

PMID:
25908644
3.

miRSNP-Based Approach Identifies a miRNA That Regulates Prostate-Specific Antigen in an Allele-Specific Manner.

Yousef GM.

Cancer Discov. 2015 Apr;5(4):351-2. doi: 10.1158/2159-8290.CD-15-0230.

PMID:
25847955
4.

Urinary biomarkers for the detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.

Sequeiros T, Bastarós JM, Sánchez M, Rigau M, Montes M, Placer J, Planas J, de Torres I, Reventós J, Pegtel DM, Doll A, Morote J, Olivan M.

Prostate. 2015 Jul 1;75(10):1102-13. doi: 10.1002/pros.22995. Epub 2015 Apr 1.

PMID:
25845829
5.

Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.

Fernandez EV, Reece KM, Ley AM, Troutman SM, Sissung TM, Price DK, Chau CH, Figg WD.

Mol Pharmacol. 2015 Jun;87(6):1006-12. doi: 10.1124/mol.114.097477. Epub 2015 Mar 31.

6.

KDM1A triggers androgen-induced miRNA transcription via H3K4me2 demethylation and DNA oxidation.

Yang S, Zhang J, Zhang Y, Wan X, Zhang C, Huang X, Huang W, Pu H, Pei C, Wu H, Huang Y, Huang S, Li Y.

Prostate. 2015 Jun 15;75(9):936-46. doi: 10.1002/pros.22977. Epub 2015 Mar 1.

PMID:
25728837
7.

Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases.

Helfand BT, Roehl KA, Cooper PR, McGuire BB, Fitzgerald LM, Cancel-Tassin G, Cornu JN, Bauer S, Van Blarigan EL, Chen X, Duggan D, Ostrander EA, Gwo-Shu M, Zhang ZF, Chang SC, Jeong S, Fontham ET, Smith G, Mohler JL, Berndt SI, McDonnell SK, Kittles R, Rybicki BA, Freedman M, Kantoff PW, Pomerantz M, Breyer JP, Smith JR, Rebbeck TR, Mercola D, Isaacs WB, Wiklund F, Cussenot O, Thibodeau SN, Schaid DJ, Cannon-Albright L, Cooney KA, Chanock SJ, Stanford JL, Chan JM, Witte J, Xu J, Bensen JT, Taylor JA, Catalona WJ.

Hum Genet. 2015 Apr;134(4):439-50. doi: 10.1007/s00439-015-1534-9. Epub 2015 Feb 26.

PMID:
25715684
8.

A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer.

Stegeman S, Amankwah E, Klein K, O'Mara TA, Kim D, Lin HY, Permuth-Wey J, Sellers TA, Srinivasan S, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pharoah P, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Kaneva R, Teixeira MR; PRACTICAL Consortium; Australian Prostate Cancer BioResource, Spurdle AB, Clements JA, Park JY, Batra J.

Cancer Discov. 2015 Apr;5(4):368-79. doi: 10.1158/2159-8290.CD-14-1057. Epub 2015 Feb 17.

9.

Phthalates deregulate cell proliferation, but not neuroendocrine transdifferentiation, in human LNCaP prostate cancer cell model.

Hrubá E, Pernicová Z, Pálková L, Souček K, Vondráček J, Machala M.

Folia Biol (Praha). 2014;60 Suppl 1:56-61.

10.

Androgen receptor-interacting protein HSPBAP1 facilitates growth of prostate cancer cells in androgen-deficient conditions.

Saeed K, Östling P, Björkman M, Mirtti T, Alanen K, Vesterinen T, Sankila A, Lundin J, Lundin M, Rannikko A, Nordling S, Mpindi JP, Kohonen P, Iljin K, Kallioniemi O, Rantala JK.

Int J Cancer. 2015 Jun 1;136(11):2535-45. doi: 10.1002/ijc.29303. Epub 2014 Nov 20.

PMID:
25359680
11.

The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients.

He Y, Gu J, Strom S, Logothetis CJ, Kim J, Wu X.

Clin Cancer Res. 2014 Oct 1;20(19):5133-9. doi: 10.1158/1078-0432.CCR-14-0661. Erratum in: Clin Cancer Res. 2015 Oct 1;21(19):4496.

12.

Autoimmune predisposition in Down syndrome may result from a partial central tolerance failure due to insufficient intrathymic expression of AIRE and peripheral antigens.

Giménez-Barcons M, Casteràs A, Armengol Mdel P, Porta E, Correa PA, Marín A, Pujol-Borrell R, Colobran R.

J Immunol. 2014 Oct 15;193(8):3872-9. doi: 10.4049/jimmunol.1400223. Epub 2014 Sep 12.

13.

Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer.

Sowalsky AG, Xia Z, Wang L, Zhao H, Chen S, Bubley GJ, Balk SP, Li W.

Mol Cancer Res. 2015 Jan;13(1):98-106. doi: 10.1158/1541-7786.MCR-14-0273. Epub 2014 Sep 4.

14.

Redox and catalysis 'all-in-one' infinite coordination polymer for electrochemical immunosensor of tumor markers.

Zhang B, Liu B, Chen G, Tang D.

Biosens Bioelectron. 2015 Feb 15;64:6-12. doi: 10.1016/j.bios.2014.08.024. Epub 2014 Aug 19.

PMID:
25173732
15.

Analysis of androgen and anti-androgen regulation of KLK-related peptidase 2, 3, and 4 alternative transcripts in prostate cancer.

Lai J, An J, Nelson CC, Lehman ML, Batra J, Clements JA.

Biol Chem. 2014 Sep;395(9):1127-32. doi: 10.1515/hsz-2014-0149.

PMID:
25153393
16.

Kallikreins are involved in an miRNA network that contributes to prostate cancer progression.

Samaan S, Lichner Z, Ding Q, Saleh C, Samuel J, Streutker C, Yousef GM.

Biol Chem. 2014 Sep;395(9):991-1001. doi: 10.1515/hsz-2013-0288.

PMID:
25153383
17.

KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment.

Dijkstra S, Leyten GH, Jannink SA, de Jong H, Mulders PF, van Oort IM, Schalken JA.

Prostate. 2014 Sep;74(12):1222-30. doi: 10.1002/pros.22839. Epub 2014 Jul 7.

PMID:
25043536
18.

Kallikreins as biomarkers for prostate cancer.

Hong SK.

Biomed Res Int. 2014;2014:526341. doi: 10.1155/2014/526341. Epub 2014 Apr 7. Review.

19.

Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation.

Hsieh CL, Fei T, Chen Y, Li T, Gao Y, Wang X, Sun T, Sweeney CJ, Lee GS, Chen S, Balk SP, Liu XS, Brown M, Kantoff PW.

Proc Natl Acad Sci U S A. 2014 May 20;111(20):7319-24. doi: 10.1073/pnas.1324151111. Epub 2014 Apr 28.

20.

Kallikrein 3 and vitamin D receptor polymorphisms: potentials environmental risk factors for prostate cancer.

Hu J, Qiu Z, Zhang L, Cui F.

Diagn Pathol. 2014 Apr 22;9:84. doi: 10.1186/1746-1596-9-84.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk